Nicolas A. Brozzi

Nicolas A. Brozzi

Auto-generated profile, based on publicly available information

Nicolas A. Brozzi

Cleveland Clinic Florida

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2021 in Journal of Cardiac Surgery
Verified
Journal Article
Closed access
PDF file
RARene Aleman
Rene Aleman
SPSinal Patel
Sinal Patel
JSJose Sleiman
Jose Sleiman
JNJose Navia
Jose Navia
CSCedric Sheffield
Cedric Sheffield
NBNicolas A. Brozzi
Nicolas A. Brozzi

14 January 2020 in Annals of Surgery
Verified
Journal Article
Closed access
NBNicolas A. Brozzi
Nicolas A. Brozzi
MLMatthias Loebe
Matthias Loebe
FSFouad Ghazi Souki
Fouad Ghazi Souki
TBThiago Beduschi
Thiago Beduschi
AGAli Ghodzisad
Ali Ghodzisad
RVRodrigo M. Vianna
Rodrigo M. Vianna
Introduction: Complexity of combined heart–liver transplantation has resulted in low adoption rates. We report a case series of adult patients receiving en-bloc heart–liver transplantation (HLTx), describe technical aspects, and discuss benefits of the technique. Methods: Retrospective review of patients receiving en-bloc HLTx over 18 months, with clinical follow up to 1 year. Primary outcomes included postoperative mortality and major complications. Secondary outcomes included 1-year survival, cardiac or hepatic allograft rejection, and infection. Results: Five patients received en-bloc HLTx. Mean recipient age was 43 years (26–63), and 3 patients were male. Total operative time was 430 minutes (393–480), cold and warm ischemic times of 85 (32–136) and 37.5 (31–47) minutes. Hospital survival was 80%. One patient died on postoperative day 55 due to fungal sepsis. Major postoperative complications included prolonged mechanical ventilation in 2 of 5 patients (40%), and renal insufficiency requiring hemodialysis in 2 of 5 patients (40%). Among patients discharged from hospital 1-year survival was 100%, with no evidence of rejection or infectious complications. Conclusion: En-bloc HLTx technique is a safe and effective strategy, decreasing operative times, and allograft ischemic times, whereas offering protection of implanted allografts during early stages of reperfusion while patient is hemodynamically supported on cardiopulmonary bypass.

13 August 2020 in Frontiers in Physiology
Verified
Journal Article
Open access
PDF file
CICamila Iansen Irion
Camila Iansen Irion
JDJulian C. Dunkley
Julian C. Dunkley
KJKrista John-Williams
Krista John-Williams
JCJosé Manuel Condor Capcha
José Manuel Condor Capcha
SSSerene A. Shehadeh
Serene A. Shehadeh
LSLina A Shehadeh
Lina A Shehadeh
Background: Heart transplant is the gold standard therapy for patients with advanced heart failure. Over 5,500 heart transplants are performed every year worldwide. Cardiac allograft vasculopathy (CAV) is a common complication post-heart transplant which reduces survival and often necessitates heart retransplantation. Post-transplant follow-up requires serial coronary angiography and endomyocardial biopsy (EMB) for CAV and allograft rejection screening, respectively; both of which are invasive procedures. This study aims to determine whether osteopontin (OPN) protein, a fibrosis marker often present in chronic heart disease, represents a novel biomarker for CAV. Methods: Expression of OPN was analyzed in cardiac tissue obtained from patients undergoing heart retransplantation using immunofluorescence imaging (n = 20). Tissues from native explanted hearts and three serial follow-up EMB samples of transplanted hearts were also analyzed in five of these patients. Results: Fifteen out of 20 patients undergoing retransplantation had CAV. 13/15 patients with CAV expressed nuclear OPN. 5/5 patients with multiple tissue samples expressed nuclear OPN in both 1st and 2nd explanted hearts, while 0/5 expressed nuclear OPN in any of the follow-up EMBs. 4/5 of these patients had an initial diagnosis of dilated cardiomyopathy (DCM). Conclusion: Nuclear localization of OPN in cardiomyocytes of patients with CAV was evident at the time of cardiac retransplant as well as in patients with DCM at the time of the 1st transplant. The results implicate nuclear OPN as a novel biomarker for severe CAV and DCM.

21 October 2021 in Heart Failure Reviews
Verified
Journal Article
Closed access
PDF file
BVBernardo Perez Villa
Bernardo Perez Villa
RCRoberto J. Cubeddu
Roberto J. Cubeddu
NBNicolas Brozzi
Nicolas Brozzi
JSJose R. Sleiman
Jose R. Sleiman
JNJose Navia
Jose Navia
JHJaime Hernandez-Montfort
Jaime Hernandez-Montfort

16 March 2022 in Journal of Patient-Reported Outcomes
Verified
Journal Article
Open access
PDF file
BVBernardo Perez Villa
Bernardo Perez Villa
SASultan Alotaibi
Sultan Alotaibi
NBNicolas Brozzi
Nicolas Brozzi
KSKurt P. Spindler
Kurt P. Spindler
JNJose Navia
Jose Navia
JHJaime Hernandez-Montfort
Jaime Hernandez-Montfort
Background: The aim of this systematic review was to describe the prognostic value of patient-reported outcome measures (PROMs) in adult heart-transplant (HT) patients. Methods: A systematic search was performed on Ovid Medline, CINAHL Plus, Web of Science, and PubMed. The study protocol was registered on the PROSPERO database (CRD42021225398), and the last search was performed on January 7, 2021. We included studies of adult HT patients where generic and disease-specific PROMs were used as prognostic indicators for survival, readmissions, HT complications, and the onset of new comorbidities. We excluded studies that used clinician-reported and patient-experience outcomes. The Quality in Prognosis Studies tool (QUIPS) was used to measure the risk of bias of the included studies. Results: We included five observational studies between 1987 and 2015, whose populations’ mean age ranged from 43 to 56 years and presented a higher proportion of males than females. The Kansas City Cardiomyopathy Questionnaire demonstrated a negative correlation with readmissions (coefficient = − 1.177, p = 0.031), and the EQ-5D showed a negative correlation with the onset of neuromuscular disease after HT (coefficient = − 0.158, p < 0.001). The Millon Behavioral Health Inventory and the Nottingham Health Profile demonstrated a statistically significant association as survival predictors (p = 0.002 and p < 0.05, respectively). A moderate overall risk of bias was reported in three studies, one study resulted in a low risk of bias, and a proportion of more than 75% of males in each of the studies. High heterogeneity between the studies impeded establishing a link between PROMs and prognostic value. Conclusion: There is low evidence supporting PROMs usage as prognostic tools in adult HT patients. Comparing outcomes of PROMS to routine prognostic in wider and systematic settings is warranted. Systematic use of PROMs in clinical settings is warranted.

16 September 2020 in Journal of Cardiac Surgery
Verified
Journal Article
Closed access
PDF file
NBNicolas A. Brozzi
Nicolas A. Brozzi
RCRenzo O. Cifuentes
Renzo O. Cifuentes
JFJose M. Figueiro
Jose M. Figueiro
AGAli Ghodsizad
Ali Ghodsizad
MLMatthias Loebe
Matthias Loebe